Some US employers are expected to drop coverage for weight-loss drugs in 2027. This decision comes as GLP-1 drugs continue to have a significant impact on the health care and business landscape.

The growing use of these drugs may be creating financial challenges for employers, leading to changes in coverage. Further details on this development are available from the source.

More information can be found on the impact of GLP-1 drugs and the resulting financial challenges for employers, as well as the expected changes in coverage for weight-loss drugs.